Physician profile
Danielle J Orr
NPI 1043427081
$2,959.95
in general payments reported to CMS, 2019-2025
34 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $405 · 2021: $14.33 · 2022: $141 · 2023: $569 · 2024: $510 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $409.57 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $368.96 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $296.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $253.42 | 2019-2025 | Evenity, Prolia, Prolia |
| Glaxosmithkline, LLC. | $176.64 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $155.52 | 2019-2025 | |
| Stryker Corporation | $150.31 | 2023 | Mako |
| Merck Sharp & Dohme LLC | $124.86 | 2019-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Astellas Pharma US INC | $97.07 | 2019-2024 | Veozah |
| Abbvie INC. | $95.78 | 2022-2025 | |
| Exact Sciences Corporation | $79.46 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.26 | 2019-2024 | Jardiance, Tradjenta |
| Sumitomo Pharma America, INC. | $65.77 | 2024-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $61.76 | 2019-2020 | |
| Allergan, INC. | $54.76 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $49.19 | 2019-2022 | |
| Mylan Specialty L.P. | $48.28 | 2020-2022 | |
| Eisai INC. | $41.82 | 2020-2024 | |
| Amarin Pharma, INC. | $41.77 | 2020 | |
| Globus Medical, INC. | $35.66 | 2025 | Senza |
| Medtronic, INC. | $32.43 | 2021-2024 | Intellis Adaptivestim |
| Axsome Therapeutics, INC. | $24.49 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $24.01 | 2023 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $22.75 | 2025 | Strensiq |
| Esperion Therapeutics, INC. | $22.19 | 2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $20.91 | 2019 | |
| Collegium Pharmaceutical, INC. | $19.96 | 2025 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $19.88 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.82 | 2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $16.27 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.74 | 2023 | Camzyos |
| Ironshore Pharmaceuticals INC. | $14.73 | 2019 | |
| Shire North American Group INC | $12.73 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.